Legend Biotech (NASDAQ: LEGN) director lists shares, options and RSUs

Rhea-AI Filing Summary

Legend Biotech Corp director Tomas J. Heyman has filed an initial ownership report outlining his equity position in the company. He directly holds 32,734 ordinary shares, which include 25,674 restricted share units that vest in staged quarterly installments beginning on March 20, 2026 and a larger tranche starting on June 20, 2026, subject to continued service. He also holds a share option over 30,000 ordinary shares at an exercise price of $23.27 per share, expiring on August 1, 2032. Of these option shares, 18,000 are immediately exercisable, with the remaining 12,000 vesting in two equal annual installments beginning on August 2, 2026. Each American Depositary Share represents two ordinary shares.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Heyman Tomas J.

(Last) (First) (Middle)

C/O LEGEND BIOTECH CORP

2101 COTTONTAIL LANE

(Street)

SOMERSET NEW JERSEY 08873

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
Legend Biotech Corp [ LEGN ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares(1)	32,734(2)	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Share Option (right to buy)	(3)	08/01/2032	Ordinary Shares	30,000	$23.27	D

Explanation of Responses:

1. The Ordinary Shares of the Issuer may be represented by American Depositary Shares ("ADSs"). Each ADS represents two ordinary shares of the Issuer.

2. Includes 25,674 restricted share units (the "RSUs"). Each RSU represents a contingent right to receive one ordinary share of the Issuer upon settlement. 7,136 RSUs have settled, with the remainder vesting (i) as to 2,100 RSUs, in 3 equal quarterly installments beginning on March 20, 2026, (ii) as to 5,888 RSUs, in 7 equal quarterly installments beginning on March 20, 2026, and (iii) as to 10,550 RSUs, with 25% of the shares vesting on June 20, 2026 with the remainder vesting in 8 equal quarterly installments thereafter, subject to the Reporting Person's continued service to the Issuer on each such vesting date.

3. 18,000 of the shares subject to the option are immediately exercisable and the remainder vest in 2 equal annual installments beginning on August 2, 2026, subject to the Reporting Person's continued service to the Issuer on each such vesting date.

Remarks:

Exhibit 24 - Power of Attorney

	/s/ James Pepin, Attorney-in-Fact	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What equity stake does Tomas J. Heyman report in Legend Biotech (LEGN)?

Tomas J. Heyman reports direct ownership of 32,734 Legend Biotech ordinary shares. This amount includes restricted share units scheduled to vest over time, reflecting a mix of currently held shares and future equity that depends on his continued service with the company.

What stock options does Tomas J. Heyman hold in Legend Biotech (LEGN)?

Heyman holds a share option over 30,000 Legend Biotech ordinary shares at $23.27 per share. The option expires on August 1, 2032. Eighteen thousand shares are immediately exercisable, while 12,000 vest in two equal annual installments beginning August 2, 2026.

How many restricted share units does Tomas J. Heyman have at Legend Biotech (LEGN)?

Heyman’s holdings include 25,674 restricted share units (RSUs) in Legend Biotech. Each RSU represents a contingent right to receive one ordinary share upon settlement, with vesting spread across multiple quarterly installments starting March 20, 2026 and June 20, 2026.

How do Legend Biotech (LEGN) American Depositary Shares relate to ordinary shares?

Legend Biotech American Depositary Shares each represent two ordinary shares of the company. This means ADS investors effectively hold exposure to twice as many underlying ordinary shares as the number of ADSs they own, based on the disclosed ratio.

When will Tomas J. Heyman’s Legend Biotech (LEGN) RSUs vest?

Heyman’s remaining RSUs vest in several quarterly tranches beginning March 20, 2026. Additional RSUs vest in equal quarterly installments starting June 20, 2026, with one large grant vesting 25% on June 20, 2026 and the rest over eight further quarterly dates.

Is Tomas J. Heyman’s Form 3 for Legend Biotech (LEGN) a buy or sell transaction?

The Form 3 reflects Tomas J. Heyman’s initial ownership in Legend Biotech, not a trade. It lists his existing ordinary shares, restricted share units, and stock options, providing transparency into his starting equity position as a director.